BioSpace News Archive

Celltex Therapeutics Corporation (“Celltex”), a Houston, Texas-based biotechnology company founded in 2011 and focused on spearheading breakthroughs in regenerative medicine using adult, autologous Mesenchymal Stem Cells (“MSCs”), today announced that it has begun active discussions with the FDA regarding a study using MSCs against Coronavirus (“COVID-19”)-type symptoms. Celltex has researched safety and efficacy from the use o

Prime Minister Justin Trudeau outlined measures today that effectively closes the border to those who are not Canadian citizens or permanent residents, with some exceptions, and to anyone showing symptoms of the coronavirus. “The CMA is encouraged to see the seriousness with which the federal government is treating the pandemic, as well

More than two-thirds of the expected number of patients have been enrolled in the TRYbeCA‑1 Phase 3 clinical trial Cash position of €73.2 million ($82.2 million) at the end of 2019 LYON, France and CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported

As part of our ongoing and aggressive commitment to address the coronavirus outbreak, the FDA updated a policy originally issued on Feb. 29 on diagnostic testing for coronavirus in order to achieve more rapid testing capacity in the U.S.

Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive Chairman and Todd Smith to be Named President and CEO of Combined Company

Only High-Throughput System to Enable Simultaneous Testing for SARS-CoV-2 and Other Common Respiratory Viruses, Boosting Efficiency and Increasing Clinical Insight

Helix BioPharma Corp., a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced its financial results for the fiscal second quarter ended January 31, 2020.

Samsung Biologics entered into a contract development and manufacturing agreement with APRINOIA Therapeutics to develop an anti-tau monoclonal antibody candidate to treat primary and secondary tauopathies, including Progressive Supranuclear Palsy and Alzheimer’s disease, which are all currently incurable.

New Diagnostics Have Potential to Increase Capacity of COVID-19 Testing in U.S. by Thousands of Tests Per Day.

InxMed Co., Ltd. announced that the company has dosed first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal melanoma or NRAS mutant metastatic melanoma at The University of Texas M. D. Anderson Cancer Center, United States.